Cardiac-tropic Lipid Nanoparticles Provide Selective Vascularization After Myocardial Infarction
Tuesday, July 15, 2025
2:54 PM – 3:05 PM EDT
Introduction: Acute myocardial infarction (AMI) is a leading cause of mortality globally, driven by thrombosis from endothelial damage under hypoxic conditions (1). Traditional VEGF-based therapies face challenges with targeted delivery and abnormal vessel formation (2). To address these, we developed CSPH-LNPs to co-deliver VEGF mRNA and PDGFRβ siRNA to ischemic heart tissue, enhancing angiogenesis and functional recovery (Fig. 1c).
Learning Objectives:
At the completion of this activity, participants will know
Screen and identify CSPH-LNPs for co-delivery of VEGF-A mRNA and PDGFRβ siRNA.
Explain the advantages of CSPH-LNPs in targeting ischemic myocardium.
Evaluate the performance of CSPH-LNPs compared to standard LNPs in myocardial infarction recovery.
